Computer modeling leads to more precise targeting of therapies —
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well-known “resistance” mutations in the gene called epidermal growth factor receptor (EGFR).
While these mutations were known for quite a long time, the question as to why they cause cancer or make some drugs ineffective was still not answered.
The study, called “Molecular Determinants of Drug-Specific Sensitivity for Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants in Non-Small Cell Lung Cancer,” and published online in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients. … Read the full story from the UC San Diego Newsroom
The senior investigator in the study was Razelle Kurzrock, MD. Dr. Kurzrock is Chief of the Division of Hematology & Oncology; Murray Professor of Medicine; Senior Deputy Director, Clinical Science and
Director, Center for Personalized Cancer Therapy and Clinical Trials Office at the UC San Diego Moores Cancer Center.